FDA 483 - Zhehai Wang - October 18, 2021

An FDA inspection of Zhehai Wang, a clinical investigator in Jinan, China, revealed a significant issue regarding the conduct of an investigation. The firm failed to conduct an investigation in accordance with the signed statement of investigator and investigational plan. This indicates a serious deviation from protocol requirements for clinical trials.